<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783859</url>
  </required_header>
  <id_info>
    <org_study_id>HOPE_V5_01022017</org_study_id>
    <nct_id>NCT02783859</nct_id>
  </id_info>
  <brief_title>Hospitalised Pneumonia With Extended Treatment (HOPE) Study</brief_title>
  <acronym>HOPE</acronym>
  <official_title>A Multi-centre Double-blind Randomised Controlled Trial to Determine if a Longer Duration of Amoxicillin-clavulanic Acid (Compared to Shorter Duration) Improves Clinical Outcomes of Children Hospitalised With Community-acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menzies School of Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Griffith University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sarawak General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queensland University of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanyang Technological University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menzies School of Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An intervention study to determine if a longer duration of antibiotics (compared to shorter
      duration) improves the short and long term clinical outcomes of children hospitalised for
      pneumonia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-centre double-blind randomised controlled trial to determine if a longer duration of
      amoxicillin-clavulanic acid (compared to shorter duration) improves the short and long term
      clinical outcomes of children hospitalised with community-acquired pneumonia, in Indigenous
      children and a developing country
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion with clinical cure (i.e. complete resolution of respiratory symptoms and signs).</measure>
    <time_frame>Clinical review week 4 (range 4-6 weeks)</time_frame>
    <description>Children will have a standardised respiratory clinical assessment, completed by either a member of the study team (doctor, research nurse), or community health centre staff member (if required) weeks is a reasonable time frame to capture clinically important outcomes. These children will be reviewed at week 4, however many children will reside in geographically isolated locations, thus a range of 4-6 weeks is a reasonable time frame to capture clinically important outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion without chronic respiratory symptoms and signs or bronchiectasis.</measure>
    <time_frame>Clinical review at 24 months (range 23-25 months)</time_frame>
    <description>Any further chronic respiratory symptoms and signs or bronchiectasis though the child's medical records (community or hospital) will be captured. These children will be reviewed at 24 months, however many children will reside in geographically isolated locations, thus a range of 23-25 months is a reasonable timeframe to capture clinically important outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to next respiratory-related hospitalisation assessed by chart reviews</measure>
    <time_frame>Chart reviews in next 12 months</time_frame>
    <description>Data will be captured through chart reviews of children's medical records (e.g. hospital and/or community health record) and/or information from parents in next 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Adverse events monitored while participant taking trial medication</time_frame>
    <description>Adverse effects will be monitored ((anorexia, nausea, vomiting, abdominal pain, diarrhoea, rashes) while children are actively taking trial medication (e.g. 8 days). Parents will also keep a diary of adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasopharyngeal bacteria antibiotic resistance patterns</measure>
    <time_frame>Baseline (admission to hospital, week 4 (range 4-6 weeks) and 12 months (range 12-14 months)</time_frame>
    <description>Nasopharyngeal respiratory antibiotic resistance will be assessed using nasal swabs. Nasopharyngeal respiratory bacterial pathogens and antibiotic resistance will be assessed using research laboratory's previously published methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole gene expression of target genes</measure>
    <time_frame>Baseline (hospital admission) and 4-6 weeks (where possible)</time_frame>
    <description>Whole genome gene expression micro-arrays will be performed in a subgroup of children (where bloods can be obtained)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Active arm: Amoxicillin-clavulanic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 days of oral amoxicillin-clavulanic Acid 400/57 duo formulation (70-90mg/kg/day, twice daily dosing: max 980mg per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 days of oral placebo (equivalent volume as the active arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-clavulanic Acid</intervention_name>
    <arm_group_label>Active arm: Amoxicillin-clavulanic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Amoxicillin-clavulanic Acid)</intervention_name>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hospitalised children aged 3-mo to 5-yrs (in Darwin, children have to be Indigenous)

          2. Have features of severe pneumonia on admission (temperature &gt;37.5 celsius or a history
             of fever at home or observed at the referring clinic, age-adjusted tachypnoea
             [respiratory rate&gt;50 if &lt;12-months; respiratory rate&gt;40 if &gt;12-months] with chest wall
             recession and/or oxygen saturation &lt;92% in air), and consolidation on chest X-ray as
             diagnosed by treating clinician

          3. After 1-3 days of IV antibiotics, are afebrile, with improved respiratory symptoms and
             signs, oxygen saturation&gt;90% in air and are ready to be switched to oral
             amoxicillin-clavulanate, and

          4. Have symptoms of no longer than 7 days at point of hospitalisation.

        Exclusion Criteria:

          1. Current wheeze

          2. Underlying chronic illness other than asthma (e.g. bronchiectasis, cyanotic congenital
             heart disease or cardiac failure, neuromuscular disorders, immunodeficiency) that
             could potentially influence the current illness

          3. Severe malnutrition (weight-for-height Z-score &lt;-3)

          4. Complicated (effusion, empyema or abscess) pneumonia, including tuberculosis

          5. Extra-pulmonary infection requiring antibiotic therapy (e.g. meningitis)

          6. Beta-lactam allergy

          7. Previously enrolled

          8. Lack a mobile phone and/or unable to return for follow-up clinic visits during the
             next 24 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Chang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menzies School of Health Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Chang, PhD</last_name>
    <phone>+61889468565</phone>
    <phone_ext>8565</phone_ext>
    <email>anne.chang@menzies.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabrielle McCallum, PhD</last_name>
    <phone>+61889468565</phone>
    <phone_ext>8565</phone_ext>
    <email>gabrielle.mccallum@menzies.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Menzies School of Health Research</name>
      <address>
        <city>Darwin</city>
        <state>Northern Territory</state>
        <zip>0812</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle McCallum, PhD</last_name>
      <phone>+61889468565</phone>
      <email>gabrielle.mccallum@menzies.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Anne Chang, PhD</last_name>
      <phone>+61889468565</phone>
      <email>anne.chang@menzies.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Anne Chang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sabah Women and Children's Hospital</name>
      <address>
        <city>Kota Kinabalu</city>
        <state>Sabah</state>
        <zip>88996</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moy Fong, MBBS</last_name>
      <phone>+60 88-522 600</phone>
      <email>fongsm@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Gabrielle McCallum, PhD</last_name>
      <phone>+61889468565</phone>
      <email>gabrielle.mccallum@menzies.edu.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Sibu</city>
        <state>Sarawak</state>
        <zip>96000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mong Ooi, MBBS MRCP</last_name>
      <phone>+6 084 343333</phone>
      <email>monghow@pd.jaring.my</email>
    </contact>
    <contact_backup>
      <last_name>Gabrielle McCallum, PhD</last_name>
      <phone>+61889468565</phone>
      <email>gabrielle.mccallum@menzies.edu.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre and Klang Hospital</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Nathan, MRCP MBBch</last_name>
      <phone>+603 7949 3643</phone>
      <email>annamarie@um.edu.my</email>
    </contact>
    <contact_backup>
      <last_name>Jessie de Bruyne, MRCP, MBBS</last_name>
      <phone>+603-79492065</phone>
      <email>debruyne@um.edu.my</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Starship Children's Hospital &amp; KidzFirst Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Byrnes, MD</last_name>
      <phone>64 9 923 9770</phone>
      <email>c.byrnes@auckland.ac.nz</email>
    </contact>
    <contact_backup>
      <last_name>Gabrielle McCallum, PhD</last_name>
      <phone>+61408866611</phone>
      <email>gabrielle.mccallum@menzies.edu.au</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <keyword>Indigenous Population</keyword>
  <keyword>Hospitals</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

